Table 1. Published studies of recent RSV vaccine candidates tested in clinical trials in different population groups.
Shaded cells signify that the study was carried out in that population. References are in parentheses.
| Vaccine | Class | Adults | Seropositive children | Seronegative children | Pregnant women | Older adults |
|---|---|---|---|---|---|---|
| FI-RSV (14, 17) | FIV* | |||||
| F, G, M subunit (89, 90] | Subunit | |||||
| F-nanoparticle (55, 81] | Nanoparticle | |||||
| Chimpanzee adenovirus RSV vaccine (39) | VVV† | |||||
| BBG2Na (91, 92) | Subunit | |||||
| ΔM2-2 (93) | LAV‡ | |||||
| rA2cp248/404/1030ΔSH (94) | LAV | |||||
| cpts530/1009 (35) | LAV | |||||
| RSV ts-2 (95) | LAV | |||||
| MEDI-559 (96) | LAV | |||||
| MEDI-534 (97–99) | LAV | |||||
| RSV ts-1 A, B, and C (100, 101) | LAV | |||||
| cpts248/955 (35) | LAV | |||||
| cp-52B (102) | LAV | |||||
| rA2cpΔNS2 (103) | LAV | |||||
| cpRSV (104, 105) | LAV | |||||
| RSV ts-1 (106–108) | LAV | |||||
| Cpts248/404 (109,110) | LAV | |||||
| rA2cp248/404ΔSH (94) | LAV | |||||
| rA2cp248/404/1030ΔNS2 (103) | LAV | |||||
| rA2cp530/1009ΔNS2 (103) | LAV | |||||
| PFP1 (111–116) | Subunit | |||||
| PFP2 (110, 117–121) | Subunit | |||||
| PFP3 (122) | Subunit | |||||
| MEDI-7510 (123) | Subunit | |||||
| F nanoparticle (124, 125) | Nanoparticle | |||||
| Pre-F (126) | Subunit | |||||
| Soluble post-F (127) | Subunit | |||||
| Small hydrophobic protein ectodomain (128) | Subunit | |||||
| RSVcps2 (129) | LAV | |||||
| LIDΔM2-2 (130) | LAV | |||||
| RSV Pre-F (131) | Recombinant |
*
FIV, formalin-inactivated vaccine.
†
VVV, viral vector vaccine.
‡
LAV, live-attenuated vaccine.